Beam Therapeutics Statistics
Share Statistics
Beam Therapeutics has 100.56M
shares outstanding. The number of shares has increased by 21.3%
in one year.
| Shares Outstanding | 100.56M |
| Shares Change (YoY) | 21.3% |
| Shares Change (QoQ) | 20.57% |
| Owned by Institutions (%) | 98.87% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,998 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 19.26M, so 19.15% of the outstanding
shares have been sold short.
| Short Interest | 19.26M |
| Short % of Shares Out | 19.15% |
| Short % of Float | 21.54% |
| Short Ratio (days to cover) | 10.76 |
Valuation Ratios
The PE ratio is -5.42 and the forward
PE ratio is -3.56.
Beam Therapeutics's PEG ratio is
-0.03.
| PE Ratio | -5.42 |
| Forward PE | -3.56 |
| PS Ratio | 32.14 |
| Forward PS | 3.7 |
| PB Ratio | 2.78 |
| P/FCF Ratio | -5.73 |
| PEG Ratio | -0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Beam Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82,
with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.82 |
| Quick Ratio | 4.82 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | -0.42 |
| Debt / FCF | -0.45 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $161,623.41 |
| Profits Per Employee | $-958,631.04 |
| Employee Count | 393 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 39K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -27.34% in the
last 52 weeks. The beta is 2.35, so Beam Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.35 |
| 52-Week Price Change | -27.34% |
| 50-Day Moving Average | 19.82 |
| 200-Day Moving Average | 24.39 |
| Relative Strength Index (RSI) | 46.63 |
| Average Volume (20 Days) | 2,410,159 |
Income Statement
In the last 12 months, Beam Therapeutics had revenue of 63.52M
and earned -376.74M
in profits. Earnings per share was -4.58.
| Revenue | 63.52M |
| Gross Profit | 41.59M |
| Operating Income | -415.57M |
| Net Income | -376.74M |
| EBITDA | -383.98M |
| EBIT | -415.57M |
| Earnings Per Share (EPS) | -4.58 |
Full Income StatementBalance Sheet
The company has 281.97M in cash and 161.43M in
debt, giving a net cash position of 120.54M.
| Cash & Cash Equivalents | 281.97M |
| Total Debt | 161.43M |
| Net Cash | 120.54M |
| Retained Earnings | -1.57B |
| Total Assets | 1.47B |
| Working Capital | 1.11B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -347.25M
and capital expenditures -8.95M, giving a free cash flow of -356.19M.
| Operating Cash Flow | -347.25M |
| Capital Expenditures | -8.95M |
| Free Cash Flow | -356.19M |
| FCF Per Share | -4.33 |
Full Cash Flow StatementMargins
Gross margin is 65.48%, with operating and profit margins of -654.25% and -593.13%.
| Gross Margin | 65.48% |
| Operating Margin | -654.25% |
| Pretax Margin | -593.06% |
| Profit Margin | -593.13% |
| EBITDA Margin | -604.51% |
| EBIT Margin | -654.25% |
| FCF Margin | -560.77% |
